# A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention

> **NCT02066415** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 667 (actual)

## Conditions studied

- Treatment for Prevention of Chronic Migraine

## Interventions

- **BIOLOGICAL:** Erenumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02066415
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-05
- **Primary completion:** 2016-02-24
- **Final completion:** 2016-04-28
- **Target enrollment:** 667 (ACTUAL)
- **Last updated:** 2022-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02066415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02066415, "A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT02066415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*